Kentaro Takanami MD, PhD, Presenter: Nothing to Disclose

Kei Takase MD, PhD, Abstract Co-Author: Nothing to Disclose

Keiichi Jingu MD, Abstract Co-Author: Nothing to Disclose

To know the mechanism, techniques and image interpretation of the radioisotope-labeled fatty acid analog, I-123 15-(p-iodophenyl)-3(R,S)-methylpentadecanoic acid (I-123 BMIPP), scintigraphy for purposes other than ischemic heart disease evaluation. To discuss the clinical role of the unusual utilization of I-123 BMIPP scintigraphy.  

A) Introduction B) Chemistry of I-123 BMIPP C) Mechanism, techniques, image interpretation and clinical utility of I-123 BMIPP scintigraphy on Myocardial imaging for assessing non-ischemic cardiomyopathy Hepatic imaging for assessing the capacity of hepatic fatty acid beta-oxidation in patients with steatohepatitis Thoracic duct imaging by orally administered I-123 BMIPP with SPECT/CT for assessing or preventing chylothorax D) Summary      

http://abstract.rsna.org/uploads/2014/14009063/14009063_tf6u.pdf

Takanami, K, Takase, K, Jingu, K, Clinical Utility of the Radioisotope-labeled Fatty Acid Analog (I-123 BMIPP) Scintigraphy beyond Ischemic Heart Disease Evaluation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14009063.html